BridgeBio Pharma BBIO Reportable Segment — Operating Income (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's reportable segment — operating income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's reportable segment — operating income (loss)?
- BridgeBio Pharma (BBIO) reported reportable segment — operating income (loss) of -$105.96M in Q1 2026.
- How has BridgeBio Pharma's reportable segment — operating income (loss) changed year-over-year?
- BridgeBio Pharma's reportable segment — operating income (loss) decreased by 1.5% year-over-year, from -$104.37M to -$105.96M.
- What does reportable segment — operating income (loss) mean?
- The profit or loss generated by the segment's core business operations.
- How do you interpret reportable segment — operating income (loss)?
- Positive values indicate a self-sustaining business, while negative values indicate a reliance on external capital to fund operations.
- How does reportable segment — operating income (loss) compare across companies?
- Standard operating income reporting for business segments.